Company Focus
Galderma
Latest Galderma News
Biotechnology
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. 18 February 2025
Dermatology News
Insights
Company Spotlight
Abeona Therapeutics is an Ohio-based biotech firm developing novel gene and cell therapies for the treatment of individuals with rare diseases.
Latest News & Features of interest to Galderma
Pharmaceutical
Spanish dermatology company Almirall was trading 4% higher on Monday afternoon after presenting its full-year 2024 financial results. 24 February 2025
Biosimilars
Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, the medicine is commercially available to patients across the USA. 24 February 2025
Pharmaceutical
US drugmaker Cosette Pharmaceuticals has entered into a definitive agreement to acquire all the outstanding shares of Australia-based Mayne Pharma with the aim of expanding its health portfolio. 21 February 2025
Pharmaceutical
Australia’s Recce Pharmaceuticals has announced positive data from a Phase II trial evaluating RECCE 327 Topical Gel (R327G) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the news pushing the firm’s shares up around 9%. 19 February 2025
Biotechnology
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. 18 February 2025
Biotechnology
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP). 18 February 2025
Biotechnology
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival (RFS). 14 February 2025
Biotechnology
Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). 14 February 2025
Biotechnology
Q32 Bio has announced a corporate restructuring, shifting its focus entirely to the development of its lead pipeline drug, bempikibart, for alopecia areata. 11 February 2025
Biotechnology
US biotech major Amgen presented its fourth quarter and 2024 financial results late Tuesday, along with its guidance for 2025. 5 February 2025
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Japanese drugmaker Shionogi is to scale up its pipeline and global ambitions with a deal worth more than $1 billion, buying the pharmaceutical operations of Japan Tobacco, including its US subsidiary Akros Pharma. 8 May 2025
21 February 2025
4 October 2024
18 September 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze